

Product datasheet for **TL313500V**

DFFB Human shRNA Lentiviral Particle (Locus ID 1677)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	DFFB Human shRNA Lentiviral Particle (Locus ID 1677)
Locus ID:	1677
Synonyms:	CAD; CPAN; DFF-40; DFF2; DFF40
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	DFFB - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 ⁷ TU/ml.
RefSeq:	NM_001004285 , NM_001004286 , NM_001282669 , NM_001320132 , NM_001320136 , NM_004402 , NR_104222 , NR_135150 , NR_135151 , NR_135152 , NM_004402.1 , NM_004402.2 , NM_004402.3 , NM_001282669.1 , NM_001004285.1 , NM_001004286.1 , BC048797 , BC048797.1 , BC032827 , NM_001282669.2
UniProt ID:	O76075
Summary:	Apoptosis is a cell death process that removes toxic and/or useless cells during mammalian development. The apoptotic process is accompanied by shrinkage and fragmentation of the cells and nuclei and degradation of the chromosomal DNA into nucleosomal units. DNA fragmentation factor (DFF) is a heterodimeric protein of 40-kD (DFFB) and 45-kD (DFFA) subunits. DFFA is the substrate for caspase-3 and triggers DNA fragmentation during apoptosis. DFF becomes activated when DFFA is cleaved by caspase-3. The cleaved fragments of DFFA dissociate from DFFB, the active component of DFF. DFFB has been found to trigger both DNA fragmentation and chromatin condensation during apoptosis. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene but the biological validity of some of these variants has not been determined. [provided by RefSeq, Sep 2013]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).